45 results about "Negative symptom" patented technology

The invention discloses a rehabilitation training evaluation system for dealing with schizophrenia patients, and relates to the technical field of data processing, the evaluation system comprises a multi-modal sensing module, an edge intelligent processing module and a dynamic graph network evaluation module; according to the technical key points, neurophysiology, behavior tracks, cognitive functions and environmental parameters are fused to form a'microscopic neural activity-mesoscopic behavior performance-macroscopic environment interaction 'full-dimension evaluation network, for example, the recessive decoupling phenomenon of'reduced brain oxygen metabolism but normal autonomic nerve function' of a negative symptom patient can be synchronously captured, and the accuracy of the evaluation network is improved. The method comprises the following steps of: firstly, quantifying the coordination and causality of data of different dimensions through a dynamic graph network, disclosing a dynamic association path of insufficient activation of a forehead cortex, social attention distraction and cognitive task error rate increase, and providing a visual basis for mechanism research and intervention target selection.

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and / or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and / or memory or certain EEG characteristics.

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and / or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and / or memory or certain EEG characteristics.

The present invention discloses a rehabilitation training evaluation system for schizophrenia patients, which relates to the field of data processing technology. The evaluation system includes a multimodal perception module, an edge intelligent processing module, and a dynamic graph network evaluation module. The technical key points are: integrating neurophysiology, behavioral trajectories, cognitive functions and environmental parameters to form a full-dimensional evaluation network of "micro-neural activity-meso-behavioral performance-macro-environment interaction". For example, it can simultaneously capture the implicit decoupling phenomenon of "reduced brain oxygen metabolism but normal autonomic nervous function" in patients with negative symptoms, avoiding the missed diagnosis of complex pathological mechanisms by traditional scales. Secondly, through the dynamic graph network, the synergy and causality of data of different dimensions are quantified, revealing the dynamic association path of "insufficient prefrontal cortex activation → social attention distraction → increased cognitive task error rate", providing a visual basis for mechanism research and intervention target selection.

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and / or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and / or memory or certain EEG characteristics.

A method is provided to bring about the necessary improvement in the user's empirical negative symptoms of schizophrenia. The calculation system can obtain a first metric associated with the user from multiple point in time. The calculation system can repeat the operation of identifying a configuration file selected based on the endpoint for improving empirical negative symptoms from multiple point in time. The calculation system can repeatedly present a set of content items identified by the configuration file to encourage the user to perform activities toward achieving the endpoint. The calculation system can obtain a second metric associated with the user from multiple point in time. If the second metric is lower than the first metric, the user is considered to have improved in the empirical negative symptoms of schizophrenia. The calculation system can enhance the effectiveness of medications the user is taking to cope with schizophrenia.

The present invention relates to novel compounds of Formula (I'), wherein P, Q, A, B, m, n, R1, R2, R9, R10, R11 and R12 are defined as in Formula (I'). These compounds may be useful as muscarinic M4 receptor subtype ("M4-mAChR") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with muscarinic M4 receptor dysfunction and diseases in which the M4 receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other disorders modulated by M4 muscarinic receptors.

Provided herein are compounds useful for treating cognitive dysfunction and negative symptoms associated with CNS disorders. In aspects, a compound of formula (I') is [Image disponible dans le document PDF, Image available in the PDF document] and the others are independently CH, CF, CCF<com:Sub>3< / com:Sub>, CCH<com:Sub>3< / com:Sub> or COCF<com:Sub>3< / com:Sub>; R<com:Sup>1< / com:Sup> is phenyl, CN, F, OCF<com:Sub>3< / com:Sub>, C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkoxy or C<com:Sub>1< / com:Sub>-C<com:Sub>5< / com:Sub> alkyl; R<com:Sup>2< / com:Sup> is H, C<com:Sub>1< / com:Sub>-C<com:Sub>5< / com:Sub> alkyl or C<com:Sub>1< / com:Sub>-C<com:Sub>5< / com:Sub> alkoxy; R<com:Sup>3< / com:Sup> is H or CH<com:Sub>3< / com:Sub>; or R<com:Sup>1< / com:Sup> and R<com:Sup>2< / com:Sup> together represent an optionally substituted 5 or 6-membered O-containing heterocyclylene, optionally substituted 5 or 6-membered O-containing heteroarylene, or optionally substituted 5 or 6-membered arylene; and R<com:Sup>4< / com:Sup> and R<com:Sup>5< / com:Sup> are independently H or C<com:Sub>1< / com:Sub>- C<com:Sub>4< / com:Sub> alkyl, or R<com:Sup>4< / com:Sup> and R<com:Sup>5< / com:Sup> together represent an optionally substituted 4-7 membered cycloalkylene or optionally substituted 5-7 membered heterocycylene. Also provided are medicaments, compositions and therapuetic uses thereof.

The present application relates to the use of roluperidone, i.e., Compound (I):and salts, solvates, pharmaceutical compositions, and dosage forms thereof, for use in methods of treating negative symptoms and disorders (e.g., autism disorders, amblyopia, personality disorders, traumatic brain injury), as well as increasing neuroplasticity and promoting neuroprotection in subjects in need thereof.

Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia.

The present invention relates to a compound for use in the treatment of schizophrenia, also known as CF3CN and referred to herein as the compound of formula I, 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazole-8-yl)benzonitrile. Preferably, the treatment of schizophrenia is the treatment of one or more symptom categories of schizophrenia. More preferably, the treatment is for the negative symptoms of schizophrenia. Alternatively, the treatment is for the cognitive symptoms of schizophrenia.

This invention discloses the application of catalpol in the preparation of drugs for the prevention and treatment of schizophrenia and the alleviation of the glucose and lipid metabolism side effects of olanzapine. Using a schizophrenia model mouse model induced by the commonly used MK801, the therapeutic effect of catalpol on schizophrenia was investigated, and the therapeutic effect of catalpol on the glucose and lipid metabolism side effects of the commonly used drug olanzapine was investigated through long-term gavage administration. A systematic study of catalpol was conducted from pharmacodynamic, behavioral, and morphological perspectives. The results showed that catalpol effectively improved the behavioral characteristics of the schizophrenia model mice, alleviated negative symptoms and cognitive impairment; catalpol effectively improved olanzapine-induced obesity and lipid metabolism disorders. This provides a theoretical research basis for the development of catalpol into a drug for the treatment of schizophrenia.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The invention relates to the field of biomedicine, and discloses application of methionine in preparation of a medicine or a composition for improving social dysfunction caused by schizophrenia. Animal experiment results show that methionine can significantly improve the social novelty recognition ability of schizophrenia model mice by adjusting methylation. The medicine is preferably an oral preparation and can also be combined with vitamin B12, folic acid and other related auxiliary factors for use. According to the invention, the potential treatment value of methionine on the negative symptoms of schizophrenia is disclosed for the first time, and a new direction is provided for developing novel mental disorder intervention medicines or nutritional compositions.

This description relates to gastro-resistant controlled-release dosage forms comprising Compound (I): (see Formula) (I), or a pharmaceutically acceptable salt and / or solvate thereof, the pharmacokinetic properties of these dosage forms, and their preparation. The novel dosage forms described herein are useful for reducing the risk of QT prolongation in a subject and for treating a disorder in a subject in need, e.g., a subject diagnosed with schizophrenia, for example, in the treatment of negative symptoms in a subject diagnosed with schizophrenia who has the CYP2D6 EM genotype.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): (I), or a pharmaceutically acceptable salt and / or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.

The invention relates to a combination comprising an effective amount of varenicline, or a salt thereof, and an effective amount of a glycine transport (GlyT) inhibitor. This combination achieves a selective dopamine increase in ventral striatum (nucleus accumbens) whilst not significantly altering dorsal striatum (associative striatum) dopamine. Such a selective dopamine elevation is of benefit for subjects suffering from schizophrenia. In particular, the combination of varenicline, or the salt thereof, and the GlyT transporter is useful for treatment of the negative symptoms in schizophrenia, without the risk of exacerbating the positive symptoms.

Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.

This invention relates to the treatment of a psychiatric or neurological disorder in a patient in need thereof who has anhedonia (lack of pleasure or motivation to pursue rewarding activities) by administering irdabisant or a pharmaceutically acceptable salt thereof, either as a monotherapy, or in combination with an antipsychotic agent. Examples of such psychiatric or neurological disorder include major depressive disorder, bipolar depression (such as bipolar I or bipolar II disorders), post-traumatic stress disorder, substance use disorder, anhedonia-related aspects of schizophrenia (e.g., negative symptoms) and schizoaffective disorder (e.g., with mood and / or negative symptoms).

The present invention relates to novel compounds of Formula (I'), wherein P, Q, A, B, m, n, R1, R2, R9, R10, R11 and R12 are defined as in Formula (I'). These compounds may be useful asmuscarinic M4 receptor subtype ("M4-mAChR") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with muscarinic M4 receptor dysfunction and diseases in which the M4 receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other disorders modulated by M4 muscarinic receptors.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

Provided in the present invention is a novel use of Pynegabine as represented by formula (I) in the preparation of drugs for treating or preventing psychiatric disorders such as depression and schizophrenia. The present invention shows that Pynegabine can exhibit a significant antidepressant effect in an acute forced swimming mouse model and a chronic social defeat stress mouse model; additionally, Pynegabine also has a significant alleviation effect on both positive and negative symptoms in an MK-801-induced mouse model of schizophrenia. The present invention shows good development and application prospects.

This invention relates to the treatment of a psychiatric or neurological disorder in a patient in need thereof who has anhedonia (lack of pleasure or motivation to pursue rewarding activities) by administering irdabisant or a pharmaceutically acceptable salt thereof, either as a monotherapy, or in combination with an antipsychotic agent. Examples of such psychiatric or neurological disorder include major depressive disorder, bipolar depression (such as bipolar I or bipolar II disorders), post-traumatic stress disorder, substance use disorder, anhedonia-related aspects of schizophrenia (e.g., negative symptoms) and schizoaffective disorder (e.g., with mood and / or negative symptoms).

The present disclosure provides compounds of Formula I: (I) or an N-oxide thereof or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7 and Z are as described herein; the present disclosure provides processes for preparing such compounds, N-oxides, or salts; intermediates useful for the preparation of such compounds, N-oxides, or salts; the present invention relates to compounds, N-oxides, or salts, and compositions containing such compounds, N-oxides, or salts, and their use for the treatment of M4-mediated (or M4-related) disorders, including, for example, Alzheimer's disease, Parkinson's disease, schizophrenia (e.g., their cognitive and negative symptoms), pain, addiction, and sleep disorders.

Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.

The present invention relates to the compound 4-(6-oxo-2-(trifluoromethyl)-3, 6-dihydrochromene [7, 8-d] imidazol-8-yl) benzonitrile, also referred to as CF3CN, referred to herein as a compound of formula I, for use in the treatment of schizophrenia. Preferably, treatment of schizophrenia is treatment of one or more symptom classes of schizophrenia. More preferably, the treatment is directed against negative symptoms of schizophrenia. Alternatively, the treatment is directed against cognitive symptoms of schizophrenia.

The present invention relates to the use of (4-benzylpiperazine-1-yl)-[2-(3-methylbutylamino) pyridin-3-yl] methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a mental disorder of depressive symptom protrusion in a selected patient exhibiting learning and / or memory impairment, the psychiatric disorders include major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g., negative symptoms). The invention also relates to the use of NSI-189, or a pharmaceutically acceptable salt thereof, in the treatment of psychiatric disorders of depressive symptoms, including major depressive disorder (MDD), in selected patients exhibiting impaired learning and / or memory or certain EEG characteristics.